The UK pharma group – now a therapeutics and vaccines pure-play since the spin-off of Haleon in July – also raised its financial forecasts for the full year for the second time in consecutive ...

Once complete, Pfizer's stake in Haleon will fall from 15.0% to around 7.3%. Pfizer's move comes after Haleon's spin-off as an independent consumer healthcare company, part of plans to reshape its ...

Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of Haleon’s issued share capital. “There will be no sale ...

In an interview with Gulf Business, Charles Leslie, global business lead for the Pain Portfolio & Systemics at Haleon, outlines key consumer health trends reshaping the healthcare sector ...